For research use only. Not for therapeutic Use.
Pepinemab (VX 15/2503) is a human monoclonal antibody against SEMA4D, a signalling protein 4D (SEMA4D), also known as CD100, which is a regulator of neuronal development and plays a role in a variety of cellular processes. Pepinemab can be used in the study of various neurodegenerative diseases such as Alzheimer’s disease by blocking the activity of SEMA4D[1].
Pepinemab(VX 15/2503) (48 h) significantly inhibits the expression of glucose transporter protein (GLUT-1) and monocarboxylate transporter protein (MCT) 4 in primary human astrocytes CC-2565 and suppresses SEMA4D-induced reduction in glucose uptake by astrocytes[1].
| Catalog Number | I042192 |
| CAS Number | 2097151-87-4 |
| Purity | ≥95% |
| Reference | [1]. Elizabeth E Evans, et al. Semaphorin 4D is upregulated in neurons of diseased brains and triggers astrocyte reactivity. J Neuroinflammation. 2022 Aug 6;19(1):200. |
